Brunch in Blue for the Angelman Syndrome Crew

Want to make a difference in the rare disease world? Join FAST and the Minnesota Angelman syndrome community on Sunday, October 11th for a brunch dedicated to raising critical funds for Angelman syndrome (AS) research. Over 150 families in Minnesota and an estimated 500,000 individuals worldwide live with this rare genetic disorder. The Edbergs of Rosemount, MN along with other families who care for a loved one living with Angelman syndrome are doing their part to raise money to help push promising science through the drug development pipeline for their loved ones – with the hope of one day having access to an approved therapeutic. 

This ticketed event is a hit year after year - you don't want to miss it! 

⭐ Wear something blue – the signature color of Angelman syndrome.

⭐ Play, raffle, and pull for prizes.

⭐ Learn, connect, and celebrate with others! 

Interested in being a sponsor or making an in-kind donation to this event? Email Meghan at will.i.can.with.angelman@gmail.com. 

ABOUT ANGELMAN SYNDROME

Angelman syndrome (AS) is a rare neurogenetic disorder that affects about one in 15,000 people, or approximately 500,000 individuals worldwide. Some say it could be as frequent as one in 8,000 people, or over 1,000,000 individuals worldwide.

People living with AS have a genetic difference on chromosome 15. People with these chromosomal changes do not produce any, or remotely enough, of something called UBE3A —which is a protein involved in brain functioning that helps us walk, talk and perform many other everyday tasks.

As a result, children and adults with AS typically have balance issues, motor impairments and can have debilitating seizures. Disruptive sleep is often a serious challenge. Some never walk. Most do not speak. Individuals with AS have a normal life expectancy but require continuous care and are unable to live independently.

ABOUT FAST

The Foundation for Angelman Syndrome Therapeutics (FAST) is the leading patient advocacy organization working to cure Angelman syndrome. Its goal is to drive forward transformative research and development programs as quickly as possible for those living with AS regardless of age or genotype.

FAST has outlined a clear Roadmap to a Cure but relies heavily on philanthropy to cover the exorbitant cost of drug development. With costs as high as $15-$25 MILLION per program, rare disease patient advocacy groups like FAST must find ways to fund these promising programs before big pharma will even consider sponsoring them.

Fundraising is a critical component to FAST's success and FAST is committed to maximizing the impact of every dollar raised, with 92 cents of every dollar invested directly into research and mission-driven programs.